4190 Investors following Jubilant Life. Share this News with them.
0
Like this story, share it with millions of investors on M3
Jubilant Organosys an outperformer: Karvy
Karvy Stock Broking has downgraded its rating on Jubilant Organosys from buy to outperformer with a target price of Rs 428. The EBITDA margins are expected to improve from 18.1% in FY08 to 19.6% in FY09E & 19.5% in FY10E mainly on account of high margin CRAMS business.
Karvy Stock Broking has downgraded its rating on Jubilant Organosys from buy to outperformer with a target price of Rs 428 in its August 26, 2008 research report. "The net revenues of the company expected to grow at a CAGR of 37% from Rs 24.9 billion in FY08 to Rs 46.8 billion in FY10E with strong growth propelling from the CRAMS and DDDS segments coupled with consistent growth from the IPP business. The EBITDA margins are expected to improve from 18.1% in FY08 to 19.6% in FY09E & 19.5% in FY10E mainly on account of high margin CRAMS business."
"Currently, the stock is quoting at 14.8x on diluted EPS of Rs.24.1 FY09E and 12.5x on diluted EPS of Rs.28.5 FY10E. We downgrade the stock from "BUY" to "Outperformer" maintaining our price target constant at Rs 428 on P/E of 15x on FY10E," says Karvy's research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
